Exscientia Plc - ADR

NASDAQ:EXAI  
18.17
-1.83 (-9.15%)
4:03:52 PM EDT: $18.18 +0.01 (+0.06%)
Other Pre-Announcement

Sanofi Collaborates With Exscientia To Develop Up To 15 New Drugs

Published: 01/07/2022 06:12 GMT
Exscientia Plc - ADR (EXAI) - Reg-exscientia and Sanofi Establish Strategic Research Collaboration to Develop Ai-driven Pipeline of Precision-engineered Medicines.
Reg-exscientia and Sanofi Establish Strategic Research Collaboration to Develop Ai-driven Pipeline of Precision-engineered Medicines.
Exscientia and Sanofi Establish Strategic Research Collaboration to Develop Ai-driven Pipeline of Precision-engineered Medicines.
Exscientia Will Receive an Upfront Cash Payment of $100 Million With Potential of $5.2 Billion in Total Milestones Plus Tiered Royalties.
Research Will Be Focused on Up to 15 Novel Small Molecule Candidates Across Oncology and Immunology.
This Upfront Cash Payment of $100 Million is Expected to Be Reflected in Q1 2022 Financial Results of Exscientia.